Gerry McCann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5049325/publications.pdf

Version: 2024-02-01

213 papers 6,688 citations

38 h-index 93651 72 g-index

219 all docs

219 docs citations

times ranked

219

8590 citing authors

#	Article	IF	CITATIONS
1	<i>PHACTR1</i> modulates vascular compliance but not endothelial function: a translational study. Cardiovascular Research, 2023, 119, 599-610.	1.8	4
2	The Interfield Strength Agreement of Left Ventricular Strain Measurements at 1. <scp>5ÂT</scp> and <scp>3ÂT</scp> Using Cardiac <scp>MRI</scp> Feature Tracking. Journal of Magnetic Resonance Imaging, 2023, 57, 1250-1261.	1.9	6
3	Benefits of sodium glucose cotransporter 2 inhibitors across the spectrum of cardiovascular diseases. Heart, 2022, 108, 16-21.	1.2	7
4	Epicardial adipose tissue in obesity-related cardiac dysfunction. Heart, 2022, 108, 339-344.	1.2	22
5	MRI and CT coronary angiography in survivors of COVID-19. Heart, 2022, 108, 46-53.	1.2	25
6	Prevalence and Disease Spectrum of Extracoronary Arterial Abnormalities in Spontaneous Coronary Artery Dissection. JAMA Cardiology, 2022, 7, 159.	3.0	18
7	Prevalence and Prognostic Significance of Microvascular Dysfunction in HeartÂFailure With Preserved EjectionAFraction. JACC: Cardiovascular Imaging, 2022, 15, 1001-1011.	2.3	25
8	Role of inflammation in diabetic cardiomyopathy. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882210835.	1.4	25
9	The impact of lifestyle intervention on left atrial function in type 2 diabetes: results from the DIASTOLIC study. International Journal of Cardiovascular Imaging, 2022, 38, 2013-2023.	0.7	2
10	Is Asymptomatic Severe Aortic Stenosis Still a Waiting Game?. Circulation, 2022, 145, 874-876.	1.6	6
11	Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. Diabetes Care, 2022, 45, 1132-1140.	4.3	4
12	Association of Myocardial Fibrosis and Stroke Volume by Cardiovascular Magnetic Resonance in Patients With Severe Aortic Stenosis With Outcome After Valve Replacement. JAMA Cardiology, 2022, 7, 513.	3.0	2
13	Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart, 2022, 108, 1200-1208.	1.2	10
14	Timing of invasive strategy in non-ST-elevation acute coronary syndrome: a meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, 3148-3161.	1.0	32
15	Very early invasive angiography versus standard of care in higher-risk non-ST elevation myocardial infarction: study protocol for the prospective multicentre randomised controlled RAPID N-STEMI trial. BMJ Open, 2022, 12, e055878.	0.8	2
16	A systematic review of <scp>microâ€RNAs</scp> in aortic stenosis and cardiac fibrosis. Clinical and Translational Science, 2022, 15, 1809-1817.	1.5	3
17	Fibroâ€inflammatory recovery and type 2 diabetes remission following a low calorie diet but not exercise training: A secondary analysis of the ⟨scp⟩DIASTOLIC⟨/scp⟩ randomised controlled trial. Diabetic Medicine, 2022, 39, e14884.	1.2	4
18	Management of asymptomatic severe aortic stenosis: a systematic review and meta-analysis. Open Heart, 2022, 9, e001982.	0.9	7

#	Article	IF	CITATIONS
19	Association of ambulatory blood pressure with coronary microvascular and cardiac dysfunction in asymptomatic type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	5
20	Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial. Cardiovascular Research, 2021, 117, 320-329.	1.8	3
21	Prevalence of right ventricular dysfunction and prognostic significance in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 255-266.	0.7	12
22	The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis. International Journal of Cardiovascular Imaging, 2021, 37, 1405-1414.	0.7	2
23	Short-term adverse remodeling progression in asymptomatic aortic stenosis. European Radiology, 2021, 31, 3923-3930.	2.3	4
24	Reproducibility of left atrial function using cardiac magnetic resonance imaging. European Radiology, 2021, 31, 2788-2797.	2.3	19
25	Cost-effectiveness of cardiovascular imaging for stable coronary heart disease. Heart, 2021, 107, 381-388.	1.2	12
26	Cardiovascular and systemic determinants of exercise capacity in people with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098023.	1.4	6
27	Sex and ethnic differences in the cardiovascular complications of type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110342.	1.4	10
28	Professor Anthony H. Gershlick. European Heart Journal, 2021, 42, 1455-1457.	1.0	0
29	Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the <scp>LYDIA</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1409-1414.	2.2	10
30	Ischemia and Infarction in Isolated Chronic Total Coronary Artery Occlusion Assessed by Cardiovascular Magnetic Resonance. JACC: Cardiovascular Imaging, 2021, 14, 501-502.	2.3	0
31	Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClinicalMedicine, 2021, 32, 100739.	3.2	36
32	Regional variation in cardiovascular magnetic resonance service delivery across the UK. Heart, 2021, 107, 1974-1979.	1.2	21
33	Plasma Pâ€selectin is a predictor of mortality in heart failure with preserved ejection fraction. ESC Heart Failure, 2021, 8, 2328-2333.	1.4	9
34	The Underrepresentation of Females in Studies Assessing the Impact of High-Dose Exercise on Cardiovascular Outcomes: a Scoping Review. Sports Medicine - Open, 2021, 7, 30.	1.3	10
35	Response by Chan et al to Radico et al Regarding Article, "Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis― Circulation: Cardiovascular Imaging, 2021, 14, e012487.	1.3	2
36	Quality assurance of quantitative cardiac T1-mapping in multicenter clinical trials – A T1 phantom program from the hypertrophic cardiomyopathy registry (HCMR) study. International Journal of Cardiology, 2021, 330, 251-258.	0.8	21

#	Article	IF	CITATIONS
37	Demographic, multi-morbidity and genetic impact on myocardial involvement and its recovery from COVID-19: protocol design of COVID-HEART—a UK, multicentre, observational study. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 77.	1.6	14
38	Assessment of stunned and viable myocardium using manganese-enhanced MRI. Open Heart, 2021, 8, e001646.	0.9	9
39	A randomized controlled trial to investigate the effects of intra-dialytic cycling on left ventricular mass. Kidney International, 2021, 99, 1478-1486.	2.6	38
40	Multi-modality assessment and role of left atrial function as an imaging biomarker in cardiovascular disease. International Journal of Cardiovascular Imaging, 2021, 37, 3355-3369.	0.7	8
41	Early invasive versus non-invasive assessment in patients with suspected non-ST-elevation acute coronary syndrome. Heart, 2021, , heartjnl-2020-318778.	1.2	4
42	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. European Heart Journal, 2021, 42, 3844-3852.	1.0	74
43	Differences in native T1 and native T2 mapping between patients on hemodialysis and control subjects. European Journal of Radiology, 2021, 140, 109748.	1.2	6
44	A comparison of liver fat fraction measurement on MRI at 3T and 1.5T. PLoS ONE, 2021, 16, e0252928.	1.1	2
45	Markers of Myocardial Damage Predict Mortality in Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2021, 78, 545-558.	1.2	41
46	Clinical associations with stage B heart failure in adults with type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110301.	1.4	2
47	Interrelationship between micronutrients and cardiovascular structure and function in type 2 diabetes. Journal of Nutritional Science, 2021, 10, e88.	0.7	2
48	A pilot randomised controlled trial of a structured, home-based exercise programme on cardiovascular structure and function in kidney transplant recipients: the ECSERT study design and methods. BMJ Open, 2021, 11, e046945.	0.8	3
49	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respiratory Medicine, the, 2021, 9, 1275-1287.	5.2	394
50	4â€Inter-modality agreement and test-retest reproducibility of CMR and Echocardiography for assessing myocardial deformation in type 2 diabetes mellitus., 2021,,.		0
51	Emerging glucose-lowering therapies: a guide for cardiologists. Heart, 2020, 106, 18-23.	1.2	6
52	Determinants of Exercise Capacity and Myocardial Perfusion Reserve in AsymptomaticÂPatients With Aortic Stenosis. JACC: Cardiovascular Imaging, 2020, 13, 178-180.	2.3	2
53	Left atrial ejection fraction and outcomes in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2020, 36, 101-110.	0.7	35
54	Combined use of trimethylamine N-oxide with BNP for risk stratification in heart failure with preserved ejection fraction: findings from the DIAMONDHFpEF study. European Journal of Preventive Cardiology, 2020, 27, 2159-2162.	0.8	32

#	Article	IF	Citations
55	Imaging Fibrosis in Aortic Stenosis. JACC: Cardiovascular Imaging, 2020, 13, 393-394.	2.3	1
56	Chronic infarct size after spontaneous coronary artery dissection: implications for pathophysiology and clinical management. European Heart Journal, 2020, 41, 2197-2205.	1.0	35
57	Cardiovascular Determinants of Aerobic Exercise Capacity in Adults With Type 2 Diabetes. Diabetes Care, 2020, 43, 2248-2256.	4.3	25
58	Manganese-enhanced magnetic resonance imaging in dilated cardiomyopathy and hypertrophic cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2020, , .	0.5	12
59	Myocardial Infarction Detection and Quantification Based on a Convolution Neural Network with Online Error Correction Capabilities. , 2020, , .		4
60	Gadobutrol-Enhanced Cardiac Magnetic Resonance Imaging for Detection of Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 1536-1547.	1.2	38
61	Fibroblastâ€growthâ€factorâ€23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes. ESC Heart Failure, 2020, 7, 4089-4099.	1.4	14
62	Plasma Tenascin-C: a prognostic biomarker in heart failure with preserved ejection fraction. Biomarkers, 2020, 25, 556-565.	0.9	15
63	Effect of the 2017 European Guidelines on Reclassification of Severe Aortic Stenosis and Its Influence on Management Decisions for Initially Asymptomatic Aortic Stenosis. Circulation: Cardiovascular Imaging, 2020, 13, e011763.	1.3	5
64	Male sex adversely affects the phenotypic expression of diabetic heart disease. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882092717.	1.4	6
65	The reliability and feasibility of non-contrast adenosine stress cardiovascular magnetic resonance T1 mapping in patients on haemodialysis. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 43.	1.6	8
66	Inter-study repeatability of circumferential strain and diastolic strain rate by CMR tagging, feature tracking and tissue tracking in ST-segment elevation myocardial infarction. International Journal of Cardiovascular Imaging, 2020, 36, 1133-1146.	0.7	13
67	Emerging Techniques for RiskÂStratification in Nonischemic DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2020, 75, 1196-1207.	1.2	25
68	A randomized, open″abel, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	2.2	13
69	Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time. Journal of the American College of Cardiology, 2020, 75, 1406-1421.	1.2	16
70	Intra-study and inter-technique validation of cardiovascular magnetic resonance imaging derived left atrial ejection fraction as a prognostic biomarker in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2020, 36, 921-928.	0.7	6
71	Extracellular Myocardial Volume in Patients With Aortic Stenosis. Journal of the American College of Cardiology, 2020, 75, 304-316.	1.2	141
72	Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach. PLoS ONE, 2020, 15, e0232280.	1.1	28

#	Article	IF	Citations
73	Effects of Low-Energy Diet or Exercise on Cardiovascular Function in Working-Age Adults With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded End Point Trial. Diabetes Care, 2020, 43, 1300-1310.	4.3	52
74	Fulminant micro and macroangiopathic sequalae in a patient with COVID-19. European Heart Journal - Case Reports, 2020, 4, 1-2.	0.3	2
75	Differential left ventricular and left atrial remodelling in heart failure with preserved ejection fraction patients with and without diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881986159.	1.4	16
76	Association between native T1 mapping of the kidney and renal fibrosis in patients with IgA nephropathy. BMC Nephrology, 2019, 20, 256.	0.8	23
77	Sex differences in left ventricular remodelling, myocardial fibrosis and mortality after aortic valve replacement. Heart, 2019, 105, 1818-1824.	1.2	30
78	The assessment of coronary artery disease in patients with end-stage renal disease. CKJ: Clinical Kidney Journal, 2019, 12, 721-734.	1.4	19
79	Aortic stenosis and diabetes mellitus: An ominous combination. Diabetes and Vascular Disease Research, 2019, 16, 310-323.	0.9	42
80	A comparison of the reproducibility of two cine-derived strain software programmes in disease states. European Journal of Radiology, 2019, 113, 51-58.	1.2	16
81	Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. New England Journal of Medicine, 2019, 380, 2418-2428.	13.9	326
82	Rationale, design and study protocol of the randomised controlled trial: Diabetes Interventional Assessment of Slimming or Training tO Lessen Inconspicuous Cardiovascular Dysfunction (the) Tj ETQq0 0 0 rg8	T/ 0. ærloc	k 119 Tf 50 37
83	Rationale and design of the randomized, controlled Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients with Severe Aortic Stenosis (EVOLVED) trial. American Heart Journal, 2019, 212, 91-100.	1.2	74
84	Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881983486.	1.4	76
85	Relationship Between Focal and DiffuseÂFibrosis Assessed by CMR and Clinical Outcomes in Heart Failure WithÂPreserved Ejection Fraction. JACC: Cardiovascular Imaging, 2019, 12, 2291-2301.	2.3	77
86	Proenkephalin and prognosis in heart failure with preserved ejection fraction: a GREAT network study. Clinical Research in Cardiology, 2019, 108, 940-949.	1.5	12
87	Leg ischaemia management collaboration (LIMb): study protocol for a prospective cohort study at a single UK centre. BMJ Open, 2019, 9, e031257.	0.8	3
88	16â€Myocardial extracellular volume in patients with aortic stenosis undergoing valve intervention: a <i>>multicentre T1 mapping study</i> >., 2019, , .		0
89	Non-ST elevation myocardial infarction, non-obstructive coronary arteries and severe regional microvascular dysfunction in a patient with dilated cardiomyopathy. BMJ Case Reports, 2019, 12, e231731.	0.2	1
90	Preoperative Cardiac Stress Testing in Patients Undergoing Vascular Surgery: Preliminary Results of a Systematic Review. European Journal of Vascular and Endovascular Surgery, 2019, 58, e616-e617.	0.8	0

#	Article	IF	CITATIONS
91	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. JAMA Network Open, 2019, 2, e1916447.	2.8	4
92	Long-Term Follow-Up of Complete Versus Lesion-Only Revascularization in STEMIÂandÂMultivessel Disease. Journal of the American College of Cardiology, 2019, 74, 3083-3094.	1.2	38
93	Haemodynamic effects of pharmacologic stress with adenosine in patients with left ventricular systolic dysfunction. International Journal of Cardiology, 2019, 278, 157-161.	0.8	4
94	Cardiac magnetic resonance imaging for the assessment of aortic stenosis. Heart, 2019, 105, 489-497.	1.2	15
95	Aortic stiffness in aortic stenosis assessed by cardiovascular MRI: a comparison between bicuspid and tricuspid valves. European Radiology, 2019, 29, 2340-2349.	2.3	13
96	Symptom Onset in Aortic Stenosis. JACC: Cardiovascular Imaging, 2019, 12, 96-105.	2.3	62
97	Relation of Aortic Stiffness to Left Ventricular Remodeling in Younger Adults With Type 2 Diabetes. Diabetes, 2018, 67, 1395-1400.	0.3	36
98	Coronary microvascular dysfunction in patients with stable coronary artery disease: The CE-MARC 2 coronary physiology sub-study. International Journal of Cardiology, 2018, 266, 7-14.	0.8	41
99	MECHANISMS IN ENDOCRINOLOGY: Diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review. European Journal of Endocrinology, 2018, 178, R127-R139.	1.9	52
100	Revisiting Reverse Remodeling AfterÂAortic Valve Replacement for Aortic Stenosis. Journal of the American College of Cardiology, 2018, 71, 872-874.	1.2	1
101	Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in heart failure with preserved ejection fraction $\hat{a} \in \text{``implications' for clinical trials. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 4.}$	1.6	62
102	Effects of Vildagliptin on Ventricular Function in Patients With TypeÂ2ÂDiabetes Mellitus and Heart Failure. JACC: Heart Failure, 2018, 6, 443-444.	1.9	1
103	Association of Medication Intensity and Stages of Airflow Limitation With the Risk of Hospitalization or Death in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JAMA Network Open, 2018, 1, e185489.	2.8	21
104	The reproducibility of cardiac magnetic resonance imaging measures of aortic stiffness and their relationship to cardiac structure in prevalent haemodialysis patients. CKJ: Clinical Kidney Journal, 2018, 11, 864-873.	1.4	8
105	Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: part I - analytical validation and clinical qualification. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 67.	1.6	101
106	Defining myocardial fibrosis in haemodialysis patients with non-contrast cardiac magnetic resonance. BMC Cardiovascular Disorders, 2018, 18, 145.	0.7	10
107	Daily remote ischaemic conditioning following acute myocardial infarction: a randomised controlled trial. Heart, 2018, 104, 1955-1962.	1.2	15
108	Myocardial Scar and Mortality in Severe Aortic Stenosis. Circulation, 2018, 138, 1935-1947.	1.6	181

#	Article	IF	CITATIONS
109	Physical activity and structured exercise in patients with type 2 diabetes mellitus and heart failure. Practical Diabetes, 2018, 35, 131.	0.1	2
110	Stroke volume index in mild-moderate aortic stenosis: more than a barometer of systolic function?. Heart, 2017, 103, 1398-1399.	1.2	2
111	Does stress perfusion imaging improve the diagnostic accuracy of late gadolinium enhanced cardiac magnetic resonance for establishing the etiology of heart failure?. BMC Cardiovascular Disorders, 2017, 17, 98.	0.7	8
112	Cardiac Remodelling in Patients Undergoing in-Centre Nocturnal Haemodialysis: Results from the MIDNIGHT Study, a Non-Randomized Controlled Trial. Blood Purification, 2017, 44, 301-310.	0.9	16
113	Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention. Value in Health, 2017, 20, 745-751.	0.1	15
114	Noninvasive Imaging Post–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2017, 10, .	1.3	1
115	Comparison of exercise testing and CMR measured myocardial perfusion reserve for predicting outcome in asymptomatic aortic stenosis: the PRognostic Importance of Microvascular Dysfunction in Aortic Stenosis (PRIMID AS) Study. European Heart Journal, 2017, 38, 1222-1229.	1.0	72
116	Infarct size following complete revascularization in patients presenting with STEMI: a comparison of immediate and staged in-hospital non-infarct related artery PCI subgroups in the CvLPRIT study. Journal of Cardiovascular Magnetic Resonance, 2017, 18, 85.	1.6	9
117	Rare finding in Takayasu arteritis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1292-1292.	0.5	1
118	The importance of accurate measurement of aortic stiffness in patients with chronic kidney disease and end-stage renal disease. CKJ: Clinical Kidney Journal, 2017, 10, 503-515.	1.4	17
119	Unusual presentation of right coronary artery fistula. BMJ Case Reports, 2017, 2017, bcr-2017-220424.	0.2	2
120	Imaging of Myocardial Fibrosis in Patients with End-Stage Renal Disease: Current Limitations and Future Possibilities. BioMed Research International, 2017, 2017, 1-14.	0.9	35
121	Cardiovascular magnetic resonance in the evaluation of heart valve disease. BMC Medical Imaging, 2017, 17, 67.	1.4	40
122	Cardiovascular magnetic resonance imaging assessment of outcomes in acute myocardial infarction. World Journal of Cardiology, 2017, 9, 109.	0.5	26
123	Myocardial strain and symptom severity in severe aortic stenosis: insights from cardiovascular magnetic resonance. Quantitative Imaging in Medicine and Surgery, 2017, 7, 38-47.	1.1	29
124	Rationale and design of the randomised controlled trial to assess the impact of liraglutide on cardiac function and structure in young adults with type 2 diabetes (the LYDIA study). Cardiovascular Diabetology, 2016, 15, 102.	2.7	14
125	Ischemia and Infarction in STEMI Patients With Multivessel Disease. Journal of the American College of Cardiology, 2016, 67, 2698-2699.	1.2	6
126	Diagnosing Cardiac Allograft Vasculopathy. JACC: Cardiovascular Imaging, 2016, 9, 267-268.	2.3	1

#	Article	IF	Citations
127	T1 Mapping in Athletes. Circulation: Cardiovascular Imaging, 2016, 9, e004706.	1.3	3
128	Strategies to attenuate micro-vascular obstruction during P-PCI: the randomized reperfusion facilitated by local adjunctive therapy in ST-elevation myocardial infarction trial. European Heart Journal, 2016, 37, 1910-1919.	1.0	74
129	Design and methods of CYCLE-HD: improving cardiovascular health in patients with end stage renal disease using a structured programme of exercise: a randomised control trial. BMC Nephrology, 2016, 17, 69.	0.8	31
130	Effect of Care Guided by Cardiovascular Magnetic Resonance, Myocardial Perfusion Scintigraphy, or NICE Guidelines on Subsequent Unnecessary Angiography Rates. JAMA - Journal of the American Medical Association, 2016, 316, 1051.	3.8	227
131	Right ventricular function following surgical aortic valve replacement and transcatheter aortic valve implantation: A cardiovascular MR study. International Journal of Cardiology, 2016, 223, 639-644.	0.8	14
132	Novel cardiac nuclear magnetic resonance methodÂfor noninvasive assessment of myocardialÂfibrosis in hemodialysis patients. Kidney International, 2016, 90, 835-844.	2.6	62
133	Investigating the effects of 6â€months extended duration, in-centre nocturnal versus conventional haemodialysis treatment: a non-randomised, controlled feasibility study. BMJ Open, 2016, 6, e012583.	0.8	2
134	Effect of late sodium current inhibition on MRI measured diastolic dysfunction in aortic stenosis: a pilot study. BMC Research Notes, 2016, 9, 64.	0.6	5
135	Infarct Size Following Treatment With Second―Versus Thirdâ€Generation P2Y ⟨sub⟩ 12⟨/sub⟩ Antagonists in Patients With Multivessel Coronary Disease at STâ€Segment Elevation Myocardial Infarction in the CvLPRIT Study. Journal of the American Heart Association, 2016, 5, .	1.6	39
136	The use of T1 mapping to define myocardial fibrosis in haemodialysis patients. European Heart Journal Cardiovascular Imaging, 2016, 17, 832-832.	0.5	5
137	Relationship of Myocardial Strain and Markers of Myocardial Injury to Predict Segmental Recovery After Acute ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Imaging, 2016, 9, .	1.3	23
138	Gross right heart dilatation secondary to Ebstein's anomaly. Oxford Medical Case Reports, 2016, 2016, 15-16.	0.2	0
139	Ischaemic chest pain in a 65-year-old man. Heart, 2016, 102, 471-471.	1.2	O
140	Characterisation of cardiomyopathy by cardiac and aortic magnetic resonance in patients new to hemodialysis. European Radiology, 2016, 26, 2749-2761.	2.3	15
141	Native T1 mapping: inter-study, inter-observer and inter-center reproducibility in hemodialysis patients. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 21.	1.6	50
	The REFLO-STEMI (REperfusion Facilitated by LOcal adjunctive therapy in ST-Elevation Myocardial) Tj ETQq0 0 0	rgBT /Ove	rlock 10 Tf 50
142	adenosine or sodium nitroprusside with control for attenuation of microvascular obstruction during primary percutaneous coronary intervention. Efficacy and Mechanism Evaluation, 2016, 3, 1-48.	0.9	10
143	The randomised Complete versus Lesion-only PRimary percutaneous coronary Intervention Trial: Cardiovascular Magnetic Resonance imaging substudy (CvLPRIT-CMR). Efficacy and Mechanism Evaluation, 2016, 3, 1-72.	0.9	1
144	Reply. Journal of the American College of Cardiology, 2015, 66, 1745-1746.	1.2	0

#	Article	IF	Citations
145	Associations of Sedentary Time with Fat Distribution in a High-Risk Population. Medicine and Science in Sports and Exercise, 2015, 47, 1727-1734.	0.2	30
146	Epicardial adipose tissue in patients with end-stage renal disease on haemodialysis. Current Opinion in Nephrology and Hypertension, 2015, 24, 517-524.	1.0	10
147	Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. European Heart Journal Cardiovascular Imaging, 2015, 16, 763-770.	0.5	67
148	Complete Versus Lesion-Only Primary PCI. Journal of the American College of Cardiology, 2015, 66, 2713-2724.	1.2	43
149	Intertechnique agreement and interstudy reproducibility of strain and diastolic strain rate at 1.5 and 3 tesla: A comparison of featureâ€tracking and tagging in patients with aortic stenosis. Journal of Magnetic Resonance Imaging, 2015, 41, 1129-1137.	1.9	64
150	Rationale and design of the Clinical Evaluation of Magnetic Resonance Imaging in Coronary heart disease 2 trial (CE-MARC 2): A prospective, multicenter, randomized trial of diagnostic strategies in suspected coronary heart disease. American Heart Journal, 2015, 169, 17-24.e1.	1.2	25
151	Comparison of cardiovascular magnetic resonance feature tracking and tagging for the assessment of left ventricular systolic strain in acute myocardial infarction. European Journal of Radiology, 2015, 84, 840-848.	1.2	108
152	Free breathing motion-corrected T1 mapping for robust assessment of myocardial injury post myocardial infarction. International Journal of Cardiovascular Imaging, 2015, 31, 123-124.	0.7	1
153	Comparison of semi-automated methods to quantify infarct size and area at risk by cardiovascular magnetic resonance imaging at 1.5T and 3.0T field strengths. BMC Research Notes, 2015, 8, 52.	0.6	27
154	Randomized Trial of Complete Versus Lesion-Only Revascularization in Patients Undergoing Primary Percutaneous Coronary Intervention for STEMI and Multivessel Disease. Journal of the American College of Cardiology, 2015, 65, 963-972.	1.2	662
155	Novel plasma and imaging biomarkers in heart failure with preserved ejection fraction. IJC Heart and Vasculature, 2015, 9, 55-62.	0.6	5
156	Randomized Controlled Trial of Individualized Dialysate Cooling for Cardiac Protection in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1408-1417.	2.2	89
157	Reply. Journal of the American College of Cardiology, 2015, 66, 332-333.	1.2	1
158	Prospective evaluation of two novel ECG-based restitution biomarkers for prediction of sudden cardiac death risk in ischaemic cardiomyopathy. Heart, 2014, 100, 1878-1885.	1.2	25
159	The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial. Trials, 2014, 15, 371.	0.7	14
160	Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. British Journal of Clinical Pharmacology, 2014, 78, 649-659.	1.1	27
161	Voxel-wise quantification of myocardial blood flow with cardiovascular magnetic resonance: effect of variations in methodology and validation with positron emission tomography. Journal of Cardiovascular Magnetic Resonance, 2014, $16,11$.	1.6	31
162	TypeÂ2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction. Diabetic Medicine, 2014, 31, 794-798.	1.2	30

#	Article	IF	CITATIONS
163	Advances in the Understanding of the Pathophysiology and Management of Aortic Stenosis: Role of Novel Imaging Techniques. Canadian Journal of Cardiology, 2014, 30, 994-1003.	0.8	10
164	Multiparametric Cardiovascular Magnetic Resonance Assessment of Cardiac Allograft Vasculopathy. Journal of the American College of Cardiology, 2014, 63, 799-808.	1.2	82
165	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. European Heart Journal, 2014, 35, 2295-2302.	1.0	128
166	Prevalence and extent of infarct and microvascular obstruction following different reperfusion therapies in ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic Resonance, 2014, 16, 38.	1.6	31
167	Noncardiac chest pain in a patient with cardiac pathology: the importance of an accurate history. JRSM Open, 2014, 5, 204253331351891.	0.2	0
168	Prognostic MicroRNAs After AMI. Circulation Research, 2013, 113, e46-7.	2.0	6
169	MRI-safe pacemakers and reduction of cardiac MRI artefacts with right-sided implantation. European Heart Journal Cardiovascular Imaging, 2013, 14, 830-830.	0.5	3
170	Rationale and design of the PRognostic Importance of Microvascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. BMJ Open, 2013, 3, e004348.	0.8	22
171	Valvular heart disease: a call for global collaborative research initiatives. Heart, 2013, 99, 1797-1799.	1.2	7
172	Incidental finding of partial anomalous pulmonary venous drainage. European Heart Journal Cardiovascular Imaging, 2013, 14, 157-157.	0.5	0
173	MicroRNA-150. Circulation: Cardiovascular Genetics, 2013, 6, 290-298.	5.1	137
174	Comparison of local sine wave modeling with harmonic phase analysis for the assessment of myocardial strain. Journal of Magnetic Resonance Imaging, 2013, 38, 320-328.	1.9	22
175	Assessment of valve haemodynamics, reverse ventricular remodelling and myocardial fibrosis following transcatheter aortic valve implantation compared to surgical aortic valve replacement: a cardiovascular magnetic resonance study. Heart, 2013, 99, 1185-1191.	1.2	91
176	A Panel of 4 microRNAs Facilitates the Prediction of Left Ventricular Contractility after Acute Myocardial Infarction. PLoS ONE, 2013, 8, e70644.	1.1	98
177	'A one-sided affair': unilateral pulmonary oedema and the role of cardiac MRI in diagnosing premature coronary artery disease in a patient with Prader-Willi syndrome. BMJ Case Reports, 2013, 2013, bcr2013008692-bcr2013008692.	0.2	2
178	A Novel Surface Electrocardiogram–Based Marker of Ventricular Arrhythmia Risk in Patients With Ischemic Cardiomyopathy. Journal of the American Heart Association, 2012, 1, e001552.	1.6	28
179	Revascularization in patients with chronic ischaemic myocardial dysfunction: insights from cardiovascular magnetic resonance imaging. European Heart Journal Cardiovascular Imaging, 2012, 13, 985-990.	0.5	8
180	Stress cardiovascular MR in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings. British Journal of Radiology, 2012, 85, e851-e857.	1.0	18

#	Article	IF	Citations
181	Design and rationale of the MR-INFORM study: stress perfusion cardiovascular magnetic resonance imaging to guide the management of patients with stable coronary artery disease. Journal of Cardiovascular Magnetic Resonance, 2012, 14, 77.	1.6	82
182	Determinants and Functional Significance of Myocardial Perfusion Reserve in Severe Aortic Stenosis. JACC: Cardiovascular Imaging, 2012, 5, 182-189.	2.3	76
183	A Novel Surface Electrocardiogram-Based Marker of Ventricular Arrhythmia Risk in Patients With Ischemic Cardiomyopathy. Journal of the American Heart Association, 2012, 1, e001552-e001552.	1.6	4
184	MitroFast® annuloplasty ring for complete posterior mitral leaflet destruction: a novel approach in active endocarditis. Journal of Cardiovascular Surgery, 2012, 53, 401-3.	0.3	0
185	Cardiovascular magnetic resonance activity in the United Kingdom: a survey on behalf of the british society of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2011, 13, 57.	1.6	48
186	Non-invasive imaging in coronary artery disease including anatomical and functional evaluation of ischaemia and viability assessment. British Journal of Radiology, 2011, 84, S280-S295.	1.0	22
187	Managing the asymptomatic patient with severe aortic stenosis: randomised controlled trials of early surgery are overdue. Heart, 2011, 97, 1119-1121.	1.2	21
188	Giant cell myocarditis: an unusual presentation. Europace, 2011, 13, 1793-1794.	0.7	3
189	Unusual extracardiac manifestations of isolated native tricuspid valve endocarditis. BMJ Case Reports, 2010, 2010, bcr1120092502-bcr1120092502.	0.2	7
190	The seagull sign. Postgraduate Medical Journal, 2010, 86, 253-254.	0.9	2
191	Natriuretic Peptides in Common Valvular Heart Disease. Journal of the American College of Cardiology, 2010, 55, 2034-2048.	1.2	71
192	Can cutaneous telangiectasiae as late normal-tissue injury predict cardiovascular disease in women receiving radiotherapy for breast cancer?. British Journal of Cancer, 2009, 101, 403-409.	2.9	14
193	Dressler's syndrome demonstrated by late gadolinium enhancement cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2009, 11, 23.	1.6	9
194	Role of contrast-enhanced magnetic resonance imaging in detecting early adverse remodeling and subacute ventricular wall rupture complicating myocardial infarction. Heart and Vessels, 2008, 23, 430-432.	0.5	11
195	Semi-quantitative assessment of right ventricular function in comparison to a 3D volumetric approach: A cardiovascular magnetic resonance study. European Radiology, 2008, 18, 2399-2405.	2.3	39
196	Cardiac Tuberculoma. Circulation, 2008, 117, 984-986.	1.6	21
197	Sarcoidosis presenting with tachy- and brady-arrhythmias. Europace, 2007, 9, 134-136.	0.7	6
198	Extent of MRI Delayed Enhancement of Myocardial Mass Is Related to Right Ventricular Dysfunction in Pulmonary Artery Hypertension. American Journal of Roentgenology, 2007, 188, 349-355.	1.0	139

#	Article	IF	Citations
199	Lipomatous Metaplasia in Ischemic Cardiomyopathy. Circulation, 2007, 116, e5-6.	1.6	19
200	Functional Outcome after Revascularization in Patients with Chronic Ischemic Heart Disease: A Quantitative Late Gadolinium Enhancement CMR Study Evaluating Transmural Scar Extent, Wall Thickness and Periprocedural Necrosis. Journal of Cardiovascular Magnetic Resonance, 2007, 9, 815-821.	1.6	28
201	Extent of Myocardial Infarction and Reverse Remodeling Assessed by Cardiac Magnetic Resonance in Patients With and Without Right Bundle Branch Block Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2007, 99, 563-567.	0.7	21
202	NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. European Respiratory Journal, 2006, 28, 1190-1194.	3.1	72
203	Delayed Contrast-Enhanced Magnetic Resonance Imaging in Pulmonary Arterial Hypertension. Circulation, 2005, 112, e268.	1.6	41
204	Magnetic resonance imaging of recurrent left ventricular pseudoaneurysm following surgical repair. Netherlands Heart Journal, 2005, 13, 101-102.	0.3	0
205	Athletic left ventricular hypertrophy: long-term studies are required. European Heart Journal, 2000, 21, 351-353.	1.0	17
206	Responses to constant work exercise in patients with chronic heart failure. Heart, 1999, 82, 482-485.	1.2	10
207	The haemodynamic effect of the 5HT 1 agonist BMSâ€180048: a class effect of triptans?. British Journal of Clinical Pharmacology, 1999, 47, 189-194.	1.1	8
208	Hemodynamic and coronary effects of intravenous eletriptan, a 5HT -receptor agonist. Clinical Pharmacology and Therapeutics, 1999, 66, 85-90.	2.3	34
209	The Ergoreflex in patients with chronic stable heart failure. International Journal of Cardiology, 1999, 68, 157-164.	0.8	39
210	The prevalence of left ventricular hypertrophy in elite professional footballers. International Journal of Cardiology, 1999, 71, 129-134.	0.8	20
211	Effects of exercise position on the ventilatory responses to exercise in chronic heart failure. International Journal of Cardiology, 1998, 66, 59-63.	0.8	5
212	Cardiorespiratory and symptomatic variables during maximal and submaximal exercise in men with stable effort angina: a comparison of atenolol and celiprolol. European Heart Journal, 1994, 15, 1566-1570.	1.0	2
213	Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: Pathophysiology, Assessment, Prevalence and Prognosis. Cardiac Failure Review, 0, 8, .	1.2	12